Some very encouraging news for the treatment of Alzheimer’s.

Biogen Inc. announced it will seek U.S. Food and Drug Administration (FDA) approval in early 2020 for the experimental drug aducanumab after study results showed it reduced clinical decline in people living with early Alzheimer’s

After the discontinuation of the ENGAGE and EMERGE studies, more analysis of the data from these studies showed improvement in people’s cognition and function, and also in their daily life.

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes.

Read more here: